Although OBCs tend to have an immunohistochemical profile of ER-/PR-/HER2+ [8], our case presented strong reactivity for ER/PR antibodies in nearly 90 % of the tumor cells and equivocal HER2 reactivity (Score 2). This evidence concerns the gene ERBB2 and neoplasm.